Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia

Source: Sigilon press release Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A.The SIG-001 trial had been […]